S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer
S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer:An One-arm, Phase Ⅱ, Multi-center Clinical Study (SALTER TRIAL)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Wei Wang
- Phone Number: +86-0576-5199431
- Email: wei_wang2017@163.com
Study Locations
-
-
Zhejiang
-
Taizhou, Zhejiang, China, 317000
- Taizhou Hospital, Wenzhou Medical University
-
Taizhou, Zhejiang, China
- Enze Hospital
-
Taizhou, Zhejiang, China
- Sanmen People's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histological or cytologically confirmed small cell lung cancer;
- Systemic chemotherapy that has previously received at least one or more lines regimen, followed by disease progression or recurrence;
- Age 18-75 years,ECOG PS:0-2,Life expectancy of more than 3 months
- participants had at least one measurable target lesion by RECIST1.1
- The main organ function meets the following criteria:absolute value of neutrophils ≥ 1.5 × 109 / L, platelets ≥80 × 109 / L, hemoglobin ≥ 80 g / L;total bilirubin ≤ 1.5 times the upper limit of normal value, aspartate aminotransferase and alanine aminotransferase ≤ 2.5 times the upper limit of normal value (if liver metastasis, ≤ upper limit of normal value 5 times), serum creatinine ≤ 1.5 times the upper limit of normal;
- Patients should participate in the study voluntarily and sign informed consent
Exclusion Criteria:
- Patients who have been used anti-angiogenesis inhibitors,such as (such as sunitinib,bevacizumab,endostar et al.
- Subjects with symptomatic brain metastases;
- Patients whose primary lesion with active bleeding within 4 months
- Hypertension, which is uncontrolled by the drug, is defined as: systolic blood pressure ≥ 160 mmHg, or diastolic blood pressure ≥ 100 mmHg
- Patients with active or unable to control serious infections
- Patients who are pregnant or breastfeeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: S1/Anlotinib
Anlotinib 12mg qd, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until maximum 6 cycles; S1 60mg bid, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until it can not tolerate, or disease progression.
|
Anlotinib 12mg qd, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until maximum 6 cycles; S1 60mg bid, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until it can not tolerate, or disease progression.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective Response Rate (ORR)
Time Frame: each 21 days up to the toxicity or PD (up to 6 months)
|
measured by Response Evaluation Criteria in Solid Tumors version 1.1
|
each 21 days up to the toxicity or PD (up to 6 months)
|
|
progression-free survival (PFS)
Time Frame: Duration of time from the start of treatment to the first documented disease progression according to RECIST 1.1 or death due to any cause, whichever occurs first, assessed up to 12 months
|
PFS will be estimated using standard Kaplan Meier survival analysis methods.
|
Duration of time from the start of treatment to the first documented disease progression according to RECIST 1.1 or death due to any cause, whichever occurs first, assessed up to 12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival (OS)
Time Frame: Duration of time from the start of treatment to date of death, assessed up to 2 years
|
OS will be estimated using standard Kaplan Meier survival analysis methods.
|
Duration of time from the start of treatment to date of death, assessed up to 2 years
|
|
Incidence of adverse events
Time Frame: Up to 2 years
|
Incidence of adverse events per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
|
Up to 2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SALTER Trial
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.